What are the recommended pediatric dosing guidelines for niacin (nicotinic acid or nicotinamide) in infants, children, and adolescents?

Pediatric Niacin Dosing Guidelines

For children receiving parenteral nutrition, niacin should be dosed at 4-6.8 mg/kg/day for infants up to 12 months of age and 17 mg/day for older children, while therapeutic use of niacin for hypercholesterolemia in pediatric patients (≤16 years) has not been established as safe or effective by the FDA. 1, 2

Parenteral Nutrition Dosing (Evidence-Based)

For infants and children on parenteral nutrition:

• Preterm and term infants up to 12 months: 4-6.8 mg/kg/day 1
• Children over 12 months: 17 mg/day 1

These recommendations come from the 2018 ESPGHAN/ESPEN/ESPR/CSPEN guidelines on pediatric parenteral nutrition, though they acknowledge these doses are based primarily on expert opinion (Good Practice Point) rather than high-quality evidence. 1

Administration considerations for parenteral niacin:

• Should be administered daily when possible 1
• Water-soluble vitamins like niacin should ideally be added to lipid emulsions or lipid-containing mixtures to increase stability 1
• Routine monitoring of vitamin concentrations is not recommended except in patients on long-term PN (weeks), where monitoring may be needed based on clinical indications 1

Dietary Reference Intakes (For Oral Supplementation)

For adolescents and general nutritional needs:

• Males >14 years: 16 mg/day 3
• Females >14 years: 14 mg/day 3
• Pregnant adolescents: 18 mg/day 3
• Lactating adolescents: 16 mg/day 3

These are the Dietary Reference Intakes (DRI) for niacin equivalents (NE), where 1 mg nicotinamide = 1 NE. 3

Upper Intake Levels (Safety Limits)

Critical safety thresholds to prevent toxicity:

• Nicotinic acid (free form): Upper limit is 10 mg/day, derived from flushing reactions observed at 30 mg/day in young subjects 3
• Nicotinamide: Upper limit is 12.5 mg/kg body weight/day (approximately 900 mg/day for adults) 3

The distinction between nicotinic acid and nicotinamide is crucial—nicotinic acid causes flushing and potential hypotensive episodes, while nicotinamide does not produce these effects. 3

Therapeutic Use for Hypercholesterolemia (NOT Recommended)

The FDA explicitly states that safety and effectiveness of niacin therapy in pediatric patients (≤16 years) have not been established. 2

However, one retrospective study from 1993 examined therapeutic niacin use in 21 children aged 4-14 years with severe hypercholesterolemia: 4

• Doses used: 500-2250 mg daily 4
• Efficacy: Doses >1000 mg daily reduced total cholesterol by 23% and LDL cholesterol by 30% 4
• Adverse effects: Occurred in 76% of children, including reversible dose-related aminotransferase elevations in 29% 4
• Discontinuation rate: 38% stopped therapy due to flushing, abdominal pain, vomiting, headache, or elevated liver enzymes 4

This study concluded that niacin treatment should be reserved for closely-supervised treatment of severe hypercholesterolemia by a lipid specialist until long-term safety is demonstrated. 4

Critical Clinical Caveats

Niacin deficiency (pellagra) presents with:

• Cutaneous symptoms (dermatitis)
• Gastrointestinal symptoms (diarrhea)
• Neurologic symptoms (dementia)
• Can also occur in carcinoid syndrome 1

High-dose nicotinic acid toxicity (3-9 g/day) causes:

• Flushing
• Nausea and vomiting
• Liver toxicity
• Blurred vision
• Impaired glucose tolerance 1

Nicotinamide has no reported toxicity at therapeutic doses and does not cause flushing. 1